Oryzon Reports Strong AML Data but Faces Financial Tightrope
Event summary
- Iadademstat triplet combination in AML showed 100% ORR, 89% CRc, and 78% CR at EHA 2026.
- Company raised €12M post-quarter-end and secured €25M COFIDES financing commitment.
- Vafidemstat granted U.S. patent extending protection to 2043 for BPD treatment.
- Cash position stood at $16.7M as of June 30, 2026.
The big picture
Oryzon's strong AML data positions it competitively in the epigenetic oncology space, but its ability to sustain operations hinges on timely execution of COFIDES financing. The €25M commitment provides a lifeline, though the company must demonstrate continued clinical progress to maintain investor confidence amid high cash burn rates typical for biotech development stages.
What we're watching
- Regulatory Pathway
- Whether Oryzon can secure FDA agreement on ALICE-2 trial design for potential registration by year-end.
- Financial Runway
- The pace at which Oryzon burns through its $16.7M cash position before COFIDES investment materializes.
- Pipeline Diversification
- How quickly iadademstat expands into non-oncology hematology indications like essential thrombocythemia and sickle cell disease.
Related topics